Background: Paroxysmal supraventricular tachycardia (PSVT) is the second most common sustained arrhythmia with an estimated US prevalence of 2.1 million. Symptoms include palpitations, weakness or fatigue, dizziness, syncope, and chest pain. Prior studies report significantly higher healthcare resource use (HRU) and costs in newly diagnosed patients, including higher emergency department (ED) visit and inpatient admission (IP) rates and expenditures. However, the HRU burden of PSVT among prevalent patients has not been previously assessed. Objective: To define patient characteristics, HRU, and expenditures among US adults with PSVT. Methods: Enrollment, demographic, and claims data for >300 million individuals were identified from IQVIA’s PharMetrics database. Patients were 18-64 years old, were continuously enrolled with medical and prescription drug coverage from 6/1/2021 to 5/31/2024, and had 1 IP or ED claim or 2 outpatient (OP) claims with a PSVT diagnosis. Control patients with no evidence of PSVT were propensity-score matched on demographic and clinical characteristics. HRU and expenditures were measured from 6/1/2023 to 5/31/2024 and reported as mean [SD] per-patient-per-year (PPPY). Results: Among 17,112 PSVT and 17,112 matched non-PSVT patients, mean age was 51.0 years [11.1]; 64.2% were female; mean Charlson Comorbidity Index (CCI) was 0.7 [1.4]. Annual per patient expenditures were significantly higher for PSVT vs. matched non-PSVT ($26,799 [$83,110] vs. $15,613 [$52,987]; p<0.0001), reflecting higher inpatient ($7,415 [$59,487] vs. $3,546 [$33,241]; p<0.0001), outpatient ($14,182 [$39,646] vs. $7,948 [$28,559]; p<0.0001), and prescription drug ($5,202 [$20,918] vs. $4,119 [$18,245]; p<0.0001) expenditures. These higher expenditures reflected significantly higher IP admissions (0.16 [0.61] vs. 0.08 [0.41]; p<0.0001), including higher ICU stays (0.06 [3.0] vs 0.02 [0.19]; p<0.0001). A higher number of PSVT patients had at least one ED visit (31% vs non-PSVT: 18%; p<0.0001). ED visit rates were significantly higher for PSVT patients (0.61 [1.54] vs. 0.31 [0.99]; p<0.0001), as were office visit (10.82 [11.64] vs. 7.93 [9.73]; p<0.0001), OP hospital visit (3.74 [8.89] vs. 2.49 [9.11]; p<0.0001), and prescription drug fill rates (26.5 [28.7] vs. 21.1 [25.9]; p<0.0001). Conclusions: Rates of ED visits and hospital admissions are higher among US adults with PSVT, contributing to significantly higher HRU and expenditures, compared with matched adults without PSVT. Thus, these data support the impact of PSVT on patients and health systems.